secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2026-08-13T12:40:15+00:00
Accession:  0001493152-26-037605
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q2 net loss $5.9M, cash $28.4M; CTx-1301 NDA resubmission progress, Prasco deal
--------------------------------------------------------------------------------

- Cash and cash equivalents $28.4M as of June 30, 2026, up from $11.0M at Dec 31, 2025; runway into mid-2027.
- Q2 net loss $5.9M vs $5.0M YoY; six-month net loss $15.2M vs $8.8M; SG&A up 101.5% to $3.9M.
- FDA CRL on June 1, 2026 for CTx-1301 NDA requested additional CMC info; no safety/efficacy concerns; resubmission planned.
- U.S. Patent No. 12,653,791 issued June 16, 2026 covering CTx-1301, expires Dec 2042.
- Signed exclusive distribution agreement with Prasco, LLC on July 21, 2026 for CTx-1301 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/0001493152-26-037605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer